319 related articles for article (PubMed ID: 32257854)
1. Selective androgen receptor modulators: the future of androgen therapy?
Christiansen AR; Lipshultz LI; Hotaling JM; Pastuszak AW
Transl Androl Urol; 2020 Mar; 9(Suppl 2):S135-S148. PubMed ID: 32257854
[TBL] [Abstract][Full Text] [Related]
2. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications.
Solomon ZJ; Mirabal JR; Mazur DJ; Kohn TP; Lipshultz LI; Pastuszak AW
Sex Med Rev; 2019 Jan; 7(1):84-94. PubMed ID: 30503797
[TBL] [Abstract][Full Text] [Related]
3. Development of selective androgen receptor modulators (SARMs).
Narayanan R; Coss CC; Dalton JT
Mol Cell Endocrinol; 2018 Apr; 465():134-142. PubMed ID: 28624515
[TBL] [Abstract][Full Text] [Related]
4. Considerations, possible contraindications, and potential mechanisms for deleterious effect in recreational and athletic use of selective androgen receptor modulators (SARMs) in lieu of anabolic androgenic steroids: A narrative review.
Machek SB; Cardaci TD; Wilburn DT; Willoughby DS
Steroids; 2020 Dec; 164():108753. PubMed ID: 33148520
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the growing public interest in selective androgen receptor modulators.
Efimenko IV; Chertman W; Masterson TA; Dubin JM; Ramasamy R
Andrologia; 2021 Dec; 53(11):e14238. PubMed ID: 34510504
[TBL] [Abstract][Full Text] [Related]
6. [A potential of selective androgen receptor modulator(SARM)for the therapy of osteoporosis].
Yanase T
Clin Calcium; 2016 Jul; 26(7):1023-30. PubMed ID: 27346314
[TBL] [Abstract][Full Text] [Related]
7. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
[TBL] [Abstract][Full Text] [Related]
8. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
Crawford J; Prado CM; Johnston MA; Gralla RJ; Taylor RP; Hancock ML; Dalton JT
Curr Oncol Rep; 2016 Jun; 18(6):37. PubMed ID: 27138015
[TBL] [Abstract][Full Text] [Related]
9. Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile.
Rosen J; Negro-Vilar A
J Musculoskelet Neuronal Interact; 2002 Mar; 2(3):222-4. PubMed ID: 15758439
[TBL] [Abstract][Full Text] [Related]
10. Drug-Induced Liver Injury Secondary to Enobosarm: A Selective Androgen Receptor Modulator.
Weinblatt D; Roy S
J Med Cases; 2022 May; 13(5):244-248. PubMed ID: 35655632
[TBL] [Abstract][Full Text] [Related]
11. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs).
Gao W; Dalton JT
Drug Discov Today; 2007 Mar; 12(5-6):241-8. PubMed ID: 17331889
[TBL] [Abstract][Full Text] [Related]
12. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer.
Dalton JT; Taylor RP; Mohler ML; Steiner MS
Curr Opin Support Palliat Care; 2013 Dec; 7(4):345-51. PubMed ID: 24189892
[TBL] [Abstract][Full Text] [Related]
13. Selective androgen receptor modulators as function promoting therapies.
Bhasin S; Jasuja R
Curr Opin Clin Nutr Metab Care; 2009 May; 12(3):232-40. PubMed ID: 19357508
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery.
Segal S; Narayanan R; Dalton JT
Expert Opin Investig Drugs; 2006 Apr; 15(4):377-87. PubMed ID: 16548787
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
[TBL] [Abstract][Full Text] [Related]
16. Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021).
Xie Y; Tian Y; Zhang Y; Zhang Z; Chen R; Li M; Tang J; Bian J; Li Z; Xu X
Eur J Med Chem; 2022 Feb; 230():114119. PubMed ID: 35063736
[TBL] [Abstract][Full Text] [Related]
17. A novel selective androgen receptor modulator, NEP28, is efficacious in muscle and brain without serious side effects on prostate.
Akita K; Harada K; Ichihara J; Takata N; Takahashi Y; Saito K
Eur J Pharmacol; 2013 Nov; 720(1-3):107-14. PubMed ID: 24177288
[TBL] [Abstract][Full Text] [Related]
18. Tissue Selective Androgen Receptor Modulators (SARMs) Increase Pelvic Floor Muscle Mass in Ovariectomized Mice.
Ponnusamy S; Sullivan RD; Thiyagarajan T; Tillmann H; Getzenberg RH; Narayanan R
J Cell Biochem; 2017 Mar; 118(3):640-646. PubMed ID: 27681158
[TBL] [Abstract][Full Text] [Related]
19. Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials.
Fonseca GWPD; Dworatzek E; Ebner N; Von Haehling S
Expert Opin Investig Drugs; 2020 Aug; 29(8):881-891. PubMed ID: 32476495
[TBL] [Abstract][Full Text] [Related]
20. Adverse effects and potential benefits among selective androgen receptor modulators users: a cross-sectional survey.
Efimenko IV; Valancy D; Dubin JM; Ramasamy R
Int J Impot Res; 2022 Dec; 34(8):757-761. PubMed ID: 34471228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
